Clinical trials
Renal Cell Cancer Metastatic clinical trials
Below are recruiting renal cell cancer metastatic clinical trials, each written for real people, not researchers. We’re tracking 600 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05209243Recruiting
Treating limited-spread prostate cancer with radiation plus hormone therapy
This trial studies whether adding focused radiation (SBRT) to hormone therapy can control prostate cancer that has spread to only a few places. It aims to help people with early “oligometastatic” prostate cancer by improving disease control while limiting treatment side effects.
MadridAges Any age - NCT05784688RecruitingPhase 1/Phase 2
TU2218 with Keytruda for advanced solid tumors
This trial studies TU2218 taken with Keytruda (pembrolizumab) in adults with advanced solid cancers that have limited treatment options. The goal is to see if the combination can shrink tumors and is safe enough to keep using.
San Antonio, TexasAges 18 years+ - NCT04563507RecruitingPhase 2
Immunotherapy plus hormone therapy for metastatic ER-positive breast cancer
This Phase 2 study tests a combination of immune-based treatments along with hormone (endocrine) therapy to slow or shrink advanced, hormone-receptor positive, HER2-negative breast cancer. You may be a candidate if your cancer has progressed after standard hormone-blocking medicines and you can start treatment with CDK4/6 medicine plus an aromatase inhibitor.
New York, New YorkAges 18–90 - NCT06136650RecruitingPhase 3
Study of a new drug for advanced prostate cancer
This study tests a new oral drug called opevesostat against another standard hormone therapy for men with advanced prostate cancer that has spread and is no longer controlled by a first hormone therapy. It's for men who have not had chemotherapy for this stage and who have not used a PARP inhibitor or chose not to.
Tucson, ArizonaAges 18 years+ - NCT05305924RecruitingPhase 2
Fulvestrant plus abemaciclib for ER+, HER2− advanced breast cancer
This Phase 2 study tests whether adding abemaciclib to fulvestrant can slow or shrink ER-positive, HER2-negative metastatic breast cancer. It is mainly for people whose cancer has progressed despite prior treatment with a CDK4/6 inhibitor and an aromatase inhibitor.
Houston, TexasAges 18 years+ - NCT05461768RecruitingPhase 1
BL-M07D1 for HER2-positive or HER2-low breast cancer
This Phase 1 study tests BL-M07D1, a new investigational medicine, in people with HER2-positive or HER2-low breast cancer (and other solid tumors) that can’t be operated on or has spread. It aims to find a safe dose and learn how well the treatment may work based on HER2 levels in tumor tissue.
Fuzhou, FujianAges 18–75 - NCT06793553RecruitingPhase 2
Induction chemo then immunotherapy for PD-L1 positive triple negative breast cancer
This trial tests a two-step approach: first a short course of chemotherapy (paclitaxel and bevacizumab), followed by a combination of immunotherapy (atezolizumab) and a different chemotherapy (nab-paclitaxel). It's for people with advanced triple-negative breast cancer that has spread or cannot be removed, and whose tumors have a specific marker called PD-L1. The goal is to see if this sequence works better than standard treatments.
Koto-ku, 3-8-31, TokyoAges 18 years+ - NCT07258108RecruitingPhase 2
Sac-TMT and KL-A167 for HR+/HER2- Breast Cancer
This trial is testing a combination of two drugs, Sac-TMT and KL-A167, in people with a certain type of advanced breast cancer (HR+/HER2-) that is PD-L1 positive. It's for those whose cancer has gotten worse after treatment with a CDK4/6 inhibitor and hormone therapy.
Guangzhou, GuangdongAges 18–75 - NCT04704505RecruitingPhase 2
Testosterone-like treatment plus radium for bone-spread prostate cancer
This trial studies whether adding a testosterone-related therapy (BAT) to radium-223 can better control prostate cancer that has spread mainly to the bones. It may help shrink tumors in the bone and slow PSA rises, which are a common marker of prostate cancer activity.
Baltimore, MarylandAges 18 years+ - NCT07831993RecruitingPhase 2
Immunotherapy with chemotherapy for advanced bile duct cancer
This trial tests a new combination of a drug that helps your immune system fight cancer, called sintilimab, along with chemotherapy. It is for people who have bile duct cancer or gallbladder cancer that has spread to other parts of the body and have not had treatment for this stage yet. The goal is to see if this combination helps shrink tumors or stops them from growing.
Nanjing, JiangsuAges 18–75 - NCT04161664RecruitingPhase 2
Chemo for metastatic vulvar cancer with carboplatin and paclitaxel
This trial studies how well carboplatin plus paclitaxel chemotherapy works for vulvar squamous cell cancer that has spread. It may help shrink tumors and control cancer growth in people who are not able to be fully treated with local surgery.
AmsterdamAges 18 years+ - NCT04912765RecruitingPhase 2
New immune vaccine plus nivolumab for liver cancer
This trial studies whether an individualized “neoantigen” cancer vaccine given to immune cells (dendritic cells) plus nivolumab can improve outcomes in people with liver cancer and/or colorectal cancer that has spread only to the liver. It focuses on tumors that can be removed with curative surgery (with or without local ablation) and on people with good enough liver and overall health.
SingaporeAges 21 years+ - NCT05884320RecruitingPhase 2
Sacituzumab govitecan for advanced salivary gland cancers
This Phase 2 trial tests sacituzumab govitecan, an anti-cancer medicine, in people with recurrent or metastatic (coming back or spread) secretory gland cancers or related salivary gland cancers. It aims to see how well the treatment can shrink tumors and control disease when surgery or radiation is not a cure.
Houston, TexasAges 18 years+ - NCT07551050Recruiting
Sacituzumab Govitecan for Advanced HER2-Negative Breast Cancer
This trial studies how well sacituzumab govitecan (a targeted cancer drug) works for metastatic breast cancer that is HER2-negative. The study focuses on real-world patient experiences and quality of life in Chinese patients.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07034053RecruitingPhase 1/Phase 2
Clofarabine for advanced bladder cancer
This trial tests the drug clofarabine in people with advanced bladder cancer that has spread or cannot be removed by surgery. It is for those who have already tried standard treatments or chose not to have them.
ViennaAges 18 years+ - NCT06609187RecruitingPhase 1
Study of GNC-077 for advanced breast cancer and other solid tumors
This trial tests a new drug called GNC-077 for people with advanced breast cancer or other solid tumors that have spread. It aims to see if the drug is safe and effective.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06250777Enrolling by invitationPhase 2
T-DXd for HER2-mutant lung cancer with brain metastases
This trial tests a drug called T-DXd in people with advanced non-squamous lung cancer that has a specific HER2 gene change (mutation) and has spread to the brain but isn't causing symptoms. The goal is to see if the drug can shrink tumors and help control the cancer.
SeoulAges 20 years+ - NCT03990896RecruitingPhase 2
Talazoparib for metastatic breast cancer with BRCA body DNA changes
This Phase 2 trial tests talazoparib, a targeted cancer medicine, in people with metastatic breast cancer that has a harmful BRCA1 or BRCA2 mutation found in tumor DNA circulating in the blood. If you qualify, the goal is to see how well this treatment works when the mutation is detected this specific way.
San Francisco, CaliforniaAges 18 years+ - NCT05535413RecruitingPhase 1/Phase 2
UTD1 plus capecitabine for HER2-negative breast cancer brain mets
This trial tests whether adding a study drug called UTD1 to capecitabine can shrink or control breast cancer that has spread to the brain. It’s for people with HER2-negative metastatic breast cancer who have brain metastases and meet specific safety and lab requirements.
ChangshaAges 18–70 - NCT05283226RecruitingPhase 2
Oral anti-cancer pill plus paclitaxel after immunotherapy failure
This Phase 2 trial studies an oral study drug (NRC-2694-A) given with paclitaxel to treat head and neck squamous cell cancer that has come back or spread after immunotherapy. It tests whether this combination is safer and works better than expected for people whose cancer progressed on immune checkpoint inhibitors.
Fullerton, CaliforniaAges 18 years+ - NCT07129993RecruitingPhase 2/Phase 3
Study of datopotamab deruxtecan with chemo for advanced bladder cancer
This trial is testing a new drug combination for advanced bladder cancer that has grown despite previous treatment. It pairs a targeted therapy (datopotamab deruxtecan) with chemotherapy, and the goal is to see if it can slow down or stop the cancer better than standard chemo alone.
Fullerton, CaliforniaAges 18 years+ - NCT06042894RecruitingPhase 2
Study of two drugs for advanced HER2-negative breast cancer
This trial tests two experimental drugs, SI-B003 and BL-B01D1 plus SI-B003, for people with HER2-negative breast cancer that has spread or cannot be removed by surgery. It is for those who have tried standard treatments or cannot have them.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05582538RecruitingPhase 2
Ceralasertib plus immunotherapy for advanced triple-negative breast cancer
This Phase 2 trial tests whether a drug called ceralasertib can help the immune system work better, followed by durvalumab plus nab-paclitaxel. It is for people with advanced triple-negative breast cancer whose cancer returned after earlier treatment, including chemotherapy and immune therapy.
Novara, NovaraAges 18 years+ - NCT04400695RecruitingPhase 3
Targeted drug for breast cancer with low HER2 levels
This trial tests a new drug that targets breast cancer cells with low levels of the HER2 protein. It may offer a new treatment option for patients whose cancer has spread and not responded well to previous therapies.
Beijing, Beijing MunicipalityAges 18–70
Hear when a new Renal Cell Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for renal cell cancer metastatic?
- Yes. Clin2 currently lists 600 recruiting renal cell cancer metastatic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a renal cell cancer metastatic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a renal cell cancer metastatic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.